DNA
Ginkgo Bioworks Holdings
NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY
$8.34
-9.17% today
Updated 2026-06-05
Market cap
$577.47M
P/E ratio
—
P/S ratio
3.81x
EPS (TTM)
$-5.38
Dividend yield
—
52W range
$5 – $18
Volume
1.3M
Ginkgo Bioworks Holdings (DNA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$8.34
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$8.70
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.3B | $0.5B | $0.3B | $0.2B | $0.2B | $0.2B | $0.2B | $0.3B | $0.3B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 17.29% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -201.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.